Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Phase I of P-BCMA-ALLO1, a TSCM-predominant allogeneic CAR-T targeting BCMA in heavily pretreated relapsed/refractory myeloma, shows 82% (9/11) ORR, 63.6% (7/11) achieving at least VGPR, CRS in 21.2% (7/33) (all grade ≤2).”
Title: TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
Authors: Hubert Tseng, Bhagirathbhai Dholaria, Stacey A. Cranert, Maximilian Richter, Karl S. Marquez, Benjamin S. Cho, Andrew Bacong, Katherine McArthur, Jeff D. Eskew, Joanne McCaigue, Sabrina Haag, Aly Krasny, Brian Solimine, Michael J. Coffey, Aimee Loyola, Jasmine Kwong, Leyla Shune, Andrew Kin, Caitlin L. Costello, Mehmet H. Kocoglu, Aravind Ramakrishnan, Hamid Namini, Christopher E. Martin, Rajesh Belani, Julia Coronella, Devon J. Shedlock
You can read the Full Article in Nature Communications.
You can find more posts featuring Robert Orlowski on OncoDaily.
